Whether lenvatinib/lenvatinib has been included in the medical insurance policy

Lenvatinib is a multi-target tyrosine kinase inhibitor developed by Eisai of Japan. It is used to treat solid tumors such as renal cell carcinoma, hepatocellular carcinoma, thyroid cancer and certain endometrial cancers. Since the original drug was launched in China, it has been gradually included in the national medical insurance catalog due to its efficacy in various tumors and international clinical recognition. The implementation of this policy has important practical significance for patients.

According to the latest information from the National Medical Products Administration (NMPA) and the National Medical Insurance Bureau, lenvatinib has been officially included in China’s medical insurance payment coverage and is suitable for use by patients with approved specific indications. This means that under the guidance of a doctor's prescription, patients can obtain partial cost reductions through medical insurance channels, significantly reducing the economic burden of treatment. The coverage of medical insurance not only improves the accessibility of lenvatinib in China, but also promotes the clinical popularization and standardization of targeted therapy.

Overseas research and real-world data both show that lenvatinib can effectively inhibit tumor angiogenesis and cell proliferation by inhibiting VEGFR, FGFR, PDGFRα and other signaling pathways, thereby delaying disease progression. In domestic clinical practice, doctors usually adjust the dosage according to the patient's condition characteristics, tolerance and combined medication regimen to obtain the best effect. It is worth noting that medical insurance reimbursement policies usually target specific dosage forms and indications, so before taking medication, patients should confirm the specific reimbursement standards with the attending doctor or the medical insurance department.

Overall, the inclusion of lenvatinib in medical insurance not only reflects the improvement of China's treatment system, but also marks the transformation of targeted drugs into "affordable and accessible", bringing new hope to more cancer patients.

Reference materials:https://www.lenvima.com/